Tara Sanft on Managing Fear of Recurrence for Patients with Breast Cancer

Patritumab deruxtecan generated activity in patients with metastatic or unresectable EGFR-mutated non–small cell lung cancer and HER3-expressing breast cancer.

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Lasofoxifene may be helpful in managing vaginal/vulvar symptoms in women with estrogen receptor–positive/HER2-negative breast cancer harboring an ESR1 mutation.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Abemaciclib, in combination with endocrine therapy, had been approved as an adjuvant treatment for patients with high-risk, hormone receptor–positive, HER2-negative, node-positive, early breast cancer.

Sarah Donahue, MPH, AOCNP, cochair of the 40th Annual Miami Breast Cancer Conference nursing track, discusses the biggest updates in breast cancer from 2022.